Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

著者: Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell - The Lancet 2020 被引用: 142